In Situ Engineering
Engineering from Within via In Situ Programming and Regeneration
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-25-NI-08Jun 17, 2025
CDMO - Small Biotech
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
Julie Trulson, Ph.D.
PAO-02-24-CL-07Feb 15, 2024
Tech Transfer
Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies
Julie Trulson, Ph.D.
PAO-02-24-CL-06Feb 15, 2024
Anti-Idiotype Antibodies
Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development
Na Li, Ph.D.
Sino Biological
PAO-01-23-CL-01Jan 13, 2023
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05Aug 25, 2022
Polyclonal Antibodies
Advancing a New Class of Immunotherapies
SAB Biotherapeutics, Inc.
PAO-04-22-R250-70Apr 21, 2022
Oncolytic Viruses
Coverting Viruses into Therapeutic Tools
OncoMyx Therapeutics
PAO-04-22-R250-14Apr 12, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02Mar 23, 2022
Alzheimer's Vaccine
Araclon Biotech Advances in Its Innovative Vaccine and Diagnostic Test for Alzheimer's
Araclon Biotech
PR-M03-22-06Mar 15, 2022
Immunotherapy Research
Genetically Engineered Dual Receptor T-cells: Double Trouble for Cancer Cells
Juntendo University
PR-M01-22-23Jan 31, 2022
Immunotherapy
Immune Biosolutions Reports That Its Lead Immunotherapy Product IBIO123 Neutralizes 100% of the SARS-CoV-2 Variants of Concern (VOCs), Including Omicron
Immune Biosolutions
PR-M01-22-06Jan 10, 2022
Immunotherapy
Novigenix Presents New Immuno-Transcriptomic Data for Prediction of Response to Immunotherapy in Metastatic Urothelial Cancer Patients
Novigenix
PR-M09-20-21Sep 17, 2020
Immunotherapy
Leveraging the Native Immune Response to Fight Cancer
Asher Nathan
NeoTX
PAP-Q2-20-CL-017Jul 01, 2020
In Conversation
Novel Off-The-Shelf Targeted Cell Therapies
David Alvaro, Ph.D.; Sonny Hsiao, Ph.D.
Pharma's Almanac
PAP-Q2-20-CL-021Jul 01, 2020
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Gilead Sciences
PR-M05-20-NI-041May 28, 2020
PR-M03-20-NI-036
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Vaccitech Ltd.
PR-M03-20-NI-036Mar 23, 2020
In Conversation
NantKwest — Harnessing Natural Killer Cells to Treat Cancer
Emilie Branch; Patrick Soon-Shiong, M.D.
Pharma's Almanac
PAP-Q1-20-CL-016Mar 19, 2020
Launch
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Werewolf Therapeutics
PR-M11-19-NI-024Nov 20, 2019
CAR-T Immunotherapy
Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells
Cabaletta Bio
PR-M10-19-NI-024Oct 15, 2019
IND Approval
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
Precigen ActoBio
PR-M09-19-NI-006Sep 04, 2019